Intercept Pharmaceuticals (ICPT) PT Adjusted to $300 at Janney Capital; Bullish Into 2015 Catalysts
Tweet Send to a Friend
Janney Capital analyst Chiara Russo reiterated a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT) following Q4 results while updating her ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
